Advanced Melanoma - Healing Genes

Advanced Melanoma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study

Phase 1b

Doctors at the Loyola University Medical Center are recruiting patients with metastatic melanoma to trial a therapy of certain immune cells, or lymphocytes, that tend to infiltrate tumors (tumor-infiltrating lymphocytes, or TILs). These TILs will be extracted from the patient, gene-modified by a virus to better target the patient’s melanoma, and returned to the patient.

This investigatory treatment aims to assure the safety of various doses of the TILs. Patients will be monitored clinically and immunologically for a year after infusion.


  • Be 18 to 89 years of age
  • Have diagnosis of metastatic melanoma
  • Meet criteria for any prior treatments or surgical operability
  • Be HIV-negative


  1. Prescreening at the study site to confirm eligibility of the patient to participate.
  2. Apheresis, or collection of the patient’s white blood cells, will be conducted at the study site.
  3. No treatment while the cells are modified in the lab.
  4. One-time Infusion of the investigational drug made from the patient’s cells.
  5. Follow up at the study site location at a regular schedule for up to a year, assessing for adverse reactions.

The study will take place at the Loyola University Medical Center in Maywood, IL. Map.

Michael Nishimura, PhD  |  708-327-3241  |  [email protected]
Ann Lau Clark, RN, MSN  |  708-327-3221  |  [email protected]
Loyola University
National Cancer Institute (NCI)
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader